JP2013543899A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543899A5
JP2013543899A5 JP2013541073A JP2013541073A JP2013543899A5 JP 2013543899 A5 JP2013543899 A5 JP 2013543899A5 JP 2013541073 A JP2013541073 A JP 2013541073A JP 2013541073 A JP2013541073 A JP 2013541073A JP 2013543899 A5 JP2013543899 A5 JP 2013543899A5
Authority
JP
Japan
Prior art keywords
dimethylaminoethoxy
pharmaceutically acceptable
acceptable salt
cinnamoyl fumagillol
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013541073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/062413 external-priority patent/WO2012075020A1/en
Publication of JP2013543899A publication Critical patent/JP2013543899A/ja
Publication of JP2013543899A5 publication Critical patent/JP2013543899A5/ja
Pending legal-status Critical Current

Links

JP2013541073A 2010-11-29 2011-11-29 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 Pending JP2013543899A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41769210P 2010-11-29 2010-11-29
US61/417,692 2010-11-29
US201161500662P 2011-06-24 2011-06-24
US61/500,662 2011-06-24
PCT/US2011/062413 WO2012075020A1 (en) 2010-11-29 2011-11-29 Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol

Publications (2)

Publication Number Publication Date
JP2013543899A JP2013543899A (ja) 2013-12-09
JP2013543899A5 true JP2013543899A5 (OSRAM) 2015-01-08

Family

ID=45316099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541073A Pending JP2013543899A (ja) 2010-11-29 2011-11-29 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療

Country Status (10)

Country Link
US (6) US9173865B2 (OSRAM)
EP (1) EP2646016B1 (OSRAM)
JP (1) JP2013543899A (OSRAM)
KR (1) KR20140009273A (OSRAM)
CN (1) CN103379905A (OSRAM)
AU (1) AU2011336785A1 (OSRAM)
BR (1) BR112013013411A2 (OSRAM)
CA (1) CA2819251A1 (OSRAM)
MX (1) MX2013005989A (OSRAM)
WO (1) WO2012075020A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009374A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
US8772333B2 (en) 2010-01-08 2014-07-08 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
BR112013013411A2 (pt) 2010-11-29 2016-09-13 Zafgen Inc tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol
CN103402989B (zh) 2011-01-26 2016-04-06 扎夫根股份有限公司 四唑化合物及其制备和使用方法
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
KR20140040739A (ko) 2011-05-06 2014-04-03 자프겐 인크. 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン,インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
WO2014071363A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9597309B2 (en) * 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
BR112015025892A2 (pt) * 2013-04-10 2017-07-25 Syndevrx Inc inibidores de metap2 e métodos para tratar obesidade
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
US20190329042A1 (en) * 2018-02-26 2019-10-31 Daniel John DiLorenzo Method, apparatus, surgical technique, and optimal stimulation parameters for noninvasive & minimally invasive autonomic vector neuromodulation for physiologic optimization and for the treatment of obesity, cardiac disease, pulmonary disorders, hypertension, and other conditions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
KR0138530B1 (ko) 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
DE69001187T2 (de) 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (OSRAM) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
DE69330690T2 (de) 1992-01-30 2002-06-20 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
DE69311278T2 (de) 1992-12-16 1997-10-30 Takeda Chemical Industries Ltd Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
HU224028B1 (hu) 1995-03-27 2005-05-30 Assistance Publique-Hopitaux De Paris Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására
WO1997013509A1 (en) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
JP2002502814A (ja) 1997-10-31 2002-01-29 チルドレンズ・メディカル・センター・コーポレイション 血管化した正常組織の大きさおよび増殖の調節のための方法
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
AU2001253418A1 (en) 2000-04-12 2001-10-30 Smith Kline Beecham Corporation Compounds and methods
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AU2002239479B2 (en) 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2002078699A1 (en) 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US20050239878A1 (en) 2003-12-29 2005-10-27 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
CA2571683A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
JP2008528574A (ja) 2005-01-26 2008-07-31 チョン クン ダン ファーマシューティカル コープ. フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2006138475A2 (en) 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CA2690244C (en) 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
WO2010009374A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2350012B1 (en) 2008-10-06 2017-06-28 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2010048499A1 (en) 2008-10-24 2010-04-29 Wake Forest University Platinum acridine anti-cancer compounds and methods thereof
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US20120010290A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
US8772333B2 (en) * 2010-01-08 2014-07-08 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) * 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2011150338A1 (en) 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
WO2012051318A1 (en) 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
US20140011870A1 (en) 2010-11-29 2014-01-09 Zafgen, Inc. Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor
BR112013013411A2 (pt) 2010-11-29 2016-09-13 Zafgen Inc tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
CN103402989B (zh) 2011-01-26 2016-04-06 扎夫根股份有限公司 四唑化合物及其制备和使用方法
KR20140040739A (ko) 2011-05-06 2014-04-03 자프겐 인크. 삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
US9090640B2 (en) 2011-09-02 2015-07-28 Ulrich Bierbach Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof

Similar Documents

Publication Publication Date Title
JP2013543899A5 (OSRAM)
JP2015516427A5 (OSRAM)
JP2019521968A5 (OSRAM)
JP2011523412A5 (OSRAM)
JP2015515475A5 (OSRAM)
JP2010077141A5 (OSRAM)
NZ598021A (en) Prodrugs comprising an insulin linker conjugate
JP2014507477A5 (OSRAM)
JP2014505107A5 (OSRAM)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
WO2012024581A3 (en) Oxysterol compounds
JP2013508279A5 (OSRAM)
JP2010518061A5 (OSRAM)
MX2013000474A (es) Derivados de arilamida novedosos que tienen propiedades antiandrogenicas.
JP2016510326A5 (OSRAM)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2011519821A5 (ja) 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物
FI3155017T3 (fi) Parannettuja peptidilääkkeitä insuliiniresistenssiin
IL278717B1 (en) Starting dose of pth conjugates
WO2011085643A8 (zh) 吡啶并环衍生物
JP2011528334A5 (OSRAM)
JP2012502915A5 (OSRAM)
JP2013166781A5 (OSRAM)
JP2018524307A5 (OSRAM)
JP2015516419A5 (OSRAM)